Malaysian Vaccines & Pharmaceuticals Sdn. Bhd. (MVP), Malaysia’s first animal vaccine manufacturing company was established in 1992. MVP is the only, Good Manufacturing Practice (GMP) certified veterinary vaccine production plants in Malaysia. It started its activities by selling vaccines produced by the Malaysian Veterinary Research Institute (VRI) before commencing the production of animal vaccines in 1995. The vaccines were developed by VRI, University Putra Malaysia (UPM) and Arthur Webster Pty. Ltd., Australia.

In 1989, MVP (formerly known as Remee Holding) bid for the privatization project of the vaccine production unit at the VRI and also for the commercialization of UPM’s Newcastle disease vaccine Heat Resistant Strain. MVP was able to secure both bids by 1992. Under the privatization project, MVP was required to build its own plant.

Mr Muhammad of MVP with two other shareholders, Arthur Webster Pty. Ltd. and Malaysian Technology Development Corporation (MTDC) establish the plant and spearhead the establishment of the first veterinary vaccine manufacturing facility in the country. This event marked MVP’s humble beginnings. In 1995, MTDC took over the controlling stake and diversified its marketing and production activities. From its initial limited product range during its formation, MVP has progressed to a company offering wider range of vital vaccine formulations and ultimately becomes a truly high quality producer of animal prophylactics.

The Practice

The vaccine manufacturing facility was designed by Webster to meet International Standards of Good Manufacturing Facilities. These manufacturing procedural codes are strictly adhered to and as such all processes are carried out under stringent conditions of sterility to ensure the purity of the products. The Quality Assurance practices of validation, monitoring and documentation are carried out at every stage of manufacture from the receival of raw materials through to the release of goods for sale.

The starting materials for MVP’s vaccine are of the highest quality available and meet rigid specifications. A virus seed lot system is used to ensure consistency of performance for all vaccine batches. The virus seed lot has been rigorously tested for purity, safety and efficacy. The substrate used for virus growth is derived from animals, which are certified specific pathogen free (SPF). This provides assurance that the vaccine produced from these materials is free from any extraneous disease producing organisms. Added to this, all bulk virus material is rigorously tested for sterility and virus titre before incorporation into a vaccine. Selection and training of highly skilled and dedicated staffs ensures MVP’s on going commitment to quality.

Nature of Business

The company’s primary focus is on the manufacturing and marketing of animal health products and services which currently consists of high quality vaccines consisting of both live and inactivated vaccines. These vaccines are being used extensively in the poultry and swine industry as a protection against commercially debilitating diseases. To complement its products, MVP also provides technical advisory services and laboratory diagnostic services to farmers through seminars and farm visits. The services are branded under MyLAB Diagnostic Center (MyLAB). MyLAB provides various service packages through private and independent